ClinicalTrials.gov
public full text
Public Domain
Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation
To investigate limited course of treatment of Zebutinib combined with immunochemotherapy for patients with newly treated chronic lymphocytic leukemia without 17p-/TP53 mutation
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies#918292
- Zanubrutinib and Venetoclax in CLL (ZANU-VEN)#1138167
- Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma#911151
- Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)#843476
- Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax#803431
Record · ID 854693
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive